載入中
Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments. In addition to its lead candidate, the company's robust pipeline features several other therapeutic assets: CNTY-103: A CAR-iNK candidate aimed at CD133 + EGFR for recurrent glioblastoma. CNTY-102: A CAR-iT therapy targeting CD19 + CD79b, intended for relapsed or refractory B-cell lymphoma and other B-cell cancers. CNTY-104: A multi-specific CAR-iT or CAR-iNK candidate in development for acute myeloid leukemia. CNTY-106: Another multi-specific CAR-iNK or CAR-iT candidate for multiple myeloma. Established in 2018, Century Therapeutics, Inc. is based in Philadelphia, Pennsylvania.
前收盤價
US$1.47
+US$0.01 · +0.68%
盤中時間採用ET。市場資料可能有所延遲。
Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments. In addition to its lead candidate, the company's robust pipeline features several other therapeutic assets: CNTY-103: A CAR-iNK candidate aimed at CD133 + EGFR for recurrent glioblastoma. CNTY-102: A CAR-iT therapy targeting CD19 + CD79b, intended for relapsed or refractory B-cell lymphoma and other B-cell cancers. CNTY-104: A multi-specific CAR-iT or CAR-iNK candidate in development for acute myeloid leukemia. CNTY-106: Another multi-specific CAR-iNK or CAR-iT candidate for multiple myeloma. Established in 2018, Century Therapeutics, Inc. is based in Philadelphia, Pennsylvania.
日內區間
目前US$1.47
52週區間
目前US$1.47
盤中時間採用ET。市場資料可能有所延遲。
Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments. In addition to its lead candidate, the company's robust pipeline features several other therapeutic assets: CNTY-103: A CAR-iNK candidate aimed at CD133 + EGFR for recurrent glioblastoma. CNTY-102: A CAR-iT therapy targeting CD19 + CD79b, intended for relapsed or refractory B-cell lymphoma and other B-cell cancers. CNTY-104: A multi-specific CAR-iT or CAR-iNK candidate in development for acute myeloid leukemia. CNTY-106: Another multi-specific CAR-iNK or CAR-iT candidate for multiple myeloma. Established in 2018, Century Therapeutics, Inc. is based in Philadelphia, Pennsylvania.
日內區間
目前US$1.47
52週區間
目前US$1.47
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 1.09億 USD | 658.9萬 USD | 223.5萬 USD | 519.9萬 USD | — |
| 銷貨成本 | 1310.1萬 USD | — | — | — | 458.2萬 USD |
| 毛利 | 9606.3萬 USD | 658.9萬 USD | 223.5萬 USD | 519.9萬 USD | −458.2萬 USD |
| 研究與開發 | 9566.7萬 USD | 1.07億 USD | 9271萬 USD | 9717.3萬 USD | 7564.8萬 USD |
| 銷售、一般及管理費用 | 2400.3萬 USD | 3315.5萬 USD | 3470.6萬 USD | 3185.7萬 USD | 1465.3萬 USD |
| 營業費用 | 1.11億 USD | 1.45億 USD | 1.49億 USD | 1.39億 USD | 9030.1萬 USD |
| 利息收入 | 734.6萬 USD | 1300.7萬 USD | 1267.7萬 USD | 299萬 USD | 89.8萬 USD |
| 利息支出 | — | — | 54萬 USD | — | 127.5萬 USD |
| 折舊和攤銷 | 1310.1萬 USD | 1330.4萬 USD | 1304.4萬 USD | 844萬 USD | 374.8萬 USD |
| 營業利益 | −1504萬 USD | −1.38億 USD | −1.47億 USD | −1.34億 USD | −9488.3萬 USD |
| 淨利 | −958萬 USD | −1.27億 USD | −1.37億 USD | −1.31億 USD | −9582.4萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$7.50
上漲空間 410.20%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI889.66萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM450.75萬0.01%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF261.33萬0.00%954億 USD0.05%US$235+0.80%
Vanguard Russell 2000 ETFVTWO145.41萬0.01%180億 USD0.06%US$112.66+0.50%
iShares Micro-Cap ETFIWC56.37萬0.04%13.17億 USD0.60%US$183+0.11%
Vanguard Health Care ETFVHT39.35萬0.00%220億 USD0.09%US$319.01+1.64%
Invesco Russell 2000 Dynamic Multifactor ETFOMFS32.53萬0.12%2.66億 USD0.39%US$49.65+0.30%
Avantis U.S. Small Cap Equity ETFAVSC32.02萬0.01%30.82億 USD0.25%US$69.98+0.03%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCVanguard Health Care ETFVHTInvesco Russell 2000 Dynamic Multifactor ETFOMFSAvantis U.S. Small Cap Equity ETFAVSCAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
